In this Issue:
Daclizumab HYP vs interferon beta-1a in RRMS
The importance of psychosocial factors in MS
Motor network efficiency and disability in MS
Interferon beta-1a treatment and long-term outcome in RRMS
Efficacy of interferon beta vs glatiramer acetate for RRMS
Smoking cessation and MS prognosis
Epidemiology of MS
Breastfeeding and postpartum MS relapses
Fingolimod vs interferon beta/glatiramer acetate after natalizumab
Incidence and prevalence of MS in British Columbia
Please login below to download this issue (PDF)